Real-world ORGOVYX study tracks prostate cancer outcomes
Knowledge-focused
Ongoing
This study follows about 1,000 prostate cancer patients who are starting ORGOVYX as part of their routine care. Researchers will collect information on side effects, quality of life, and how the disease progresses over time. The goal is to understand how well the drug works in re…
Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:49 UTC